Multivariable analysis for role of adherence in relapse risk in African-American, Asian-American, and non-Hispanic white children with ALL
| Variables . | HR (95% CI) . | P* . |
|---|---|---|
| NCI criteria for disease risk | ||
| Standard-risk disease | 1.0 | — |
| High-risk disease | 1.2 (0.5-3.2) | .7 |
| 6MP dose intensity | ||
| Per unit increase in dose intensity | 0.99 (0.97-1.01) | .3 |
| Blast chromosomal abnormalities | ||
| Normal/ none | 1.0 | — |
| Favorable | 0.3 (0.08-1.2) | .1 |
| Unfavorable | 2.1 (0.4-10.1) | .4 |
| Adherence to oral 6MP | ||
| ≥90% | 1.0 | — |
| <90% | 3.9 (1.3-11.3) | .01 |
| Variables . | HR (95% CI) . | P* . |
|---|---|---|
| NCI criteria for disease risk | ||
| Standard-risk disease | 1.0 | — |
| High-risk disease | 1.2 (0.5-3.2) | .7 |
| 6MP dose intensity | ||
| Per unit increase in dose intensity | 0.99 (0.97-1.01) | .3 |
| Blast chromosomal abnormalities | ||
| Normal/ none | 1.0 | — |
| Favorable | 0.3 (0.08-1.2) | .1 |
| Unfavorable | 2.1 (0.4-10.1) | .4 |
| Adherence to oral 6MP | ||
| ≥90% | 1.0 | — |
| <90% | 3.9 (1.3-11.3) | .01 |
Analysis was adjusted for time from initiation of maintenance to study entry, and race.
— indicates not applicable.